Navigation Links
Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
Date:5/29/2012

ults from the ENCORE clinical program provide the basis for moving entinostat into pivotal, phase 3 testing in metastatic breast complemented by biomarker driven confirmatory studies in lung cancer.

About Syndax

Syndax is a late-stage oncology company initiating pivotal programs in solid tumors based on employing epigenetic strategies to overcome the problem of resistance in oncology care. Syndax holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor being developed in advanced breast and lung cancer. Randomized, placebo-controlled phase 2 studies with entinostat have demonstrated promising results in combination with aromatase inhibitors in breast cancer (ENCORE 301) and with the EGFR-TKI erlotinib (ENCORE 401) in non-small cell lung cancer providing the basis for moving entinostat into pivotal, phase 3 testing across a platform of solid tumor indications. NCI and Syndax are collaborating on the development of entinostat under a Cooperative Research and Development Agreement.

The company is supported by top venture capitalists and led by industry experts developing treatments for large markets including metastatic breast and lung cancer. Formed in 2005, Syndax's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. For more information please visit www.syndax.com.

Syndax Contact Information
E. Blair Schoeb
Phone: 908.277.0386
Email: bschoeb@syndax.com


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
4. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
5. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
6. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
7. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
8. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
11. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...   Plexus Information Systems, Inc. (Plexus ... Systems (AIMS), announced a partnership with NextGen ... subsidiary of Quality Systems, Inc. and a leading ... Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product portfolio ...
(Date:10/1/2014)... NOTTINGHAM, England , Oct. 1, 2014  Columbia ... that its subsidiary, Molecular Profiles Ltd., is set to ... annual CPhI/ICSE Worldwide event in Paris ... the rapid development of both standard and complex drug ... which incorporates the company,s existing formulation and analytical development ...
(Date:10/1/2014)... and NEW YORK , October 1, ... Research Organization (CRO) and service provider for the medical industries, announced ... of offices in New York City . genae ... City is strategically centered in one of the highest ... Coast", said Philippe Kassab , President at genae Americas. "The ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3genae Opens Offices in New York City 2
... a Deadly ... but Vaccine-Preventable Disease, WASHINGTON, Oct. 16 Parents ... its national,educational campaign "Silence the Sounds of Pertussis" with actress ... about the dangers of pertussis and alerts,parents to the need ...
... West Pharmaceutical,Services, Inc. (NYSE: WST ) today ... Thomas W. Hofmann. Mr. Hofmann, 56, is Senior Vice,President ... SUN ), a,position he has held since 1998. He ... largest independent,refiner-marketers of petroleum products in the United States. ...
Cached Medicine Technology:Actress and New Mom Keri Russell Joins PKIDs to launch 'Silence the Sounds of Pertussis' Campaign 2Actress and New Mom Keri Russell Joins PKIDs to launch 'Silence the Sounds of Pertussis' Campaign 3West Pharmaceutical Services, Inc. Appoints New Director 2
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... the business worldwide. This rapid growth includes increased hiring ... manufacturing efforts. The company has experienced average annual growth ... expects this growth to continue in the future as ... adoption. , “We are very pleased that ...
(Date:10/1/2014)... 01, 2014 Farmington Company today ... redefined mission and visual identity helping brokers, consultants ... with them to create greater benefit communication synergies. ... focuses on empowering customers to better leverage Farmington ... crown jewel of the rebrand is the refreshed ...
(Date:10/1/2014)... N.C. A new genetic finding from Duke Medicine ... anxiety and depression might also be hard-wired to gain ... and heart disease. , An estimated 13 percent of ... genetic susceptibility, and knowing this could help them reduce ... diet, exercise and stress management. , "Genetic susceptibility, psychosocial ...
(Date:10/1/2014)... October 01, 2014 Between 23 million ... the U.S., according to figures from the National Institutes ... Association (AARDA), and many of them have something else ... having undiagnosed celiac disease. Gluten Free Therapeutics, makers ... of undiagnosed celiac disease by publishing a series of ...
(Date:10/1/2014)... Jersey City, NJ (PRWEB) October 01, 2014 ... sticking with their intentions to lose weight and their dieting ... in unhealthy, fatty foods. Including hormone diet treatments ... not only allows patients to see fast and effective weight ... diet and begin forming healthy habits to maintain their weight ...
Breaking Medicine News(10 mins):Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... ... Saudi Arabia, SOMERSET, N.J., ... subsidiary AWT International, Inc.,has opened new sales offices in Saudi Arabia. ... U.S. healthcare industry. The Company has hired 2 highly experienced ...
... one source of frustration, study finds , TUESDAY, Oct. 9 ... U.S. Hispanics, ability to get good health care, a new ... have difficulty navigating the health care system, say researchers reporting ... , In this study, a team led by Robert Weech-Maldonado, ...
... Oct. 8, 2007 Two UT Southwestern Medical Center ... neuroscientist have been elected to the Institute of ... Sciences. , Dr. Luis Parada, professor and chairman ... chairman of neuroscience, were among 65 new national members ...
... financial and clinical ... -- Announces name change from ... Today, UPCARE Technology, Inc.,unveiled its new UPCARE(R) E2E lab performance ... of its parent company, Marquette,General Health System (MGHS). The company ...
... Oct. 9 Many Americans are obsessed with,staying in ... being,mentally fit. More Americans are becoming aware of the ... knowledge, intelligence, and quick,wits are rewarded. Being mentally fit ... train your brain have been lacking,until recently. A ...
... Award-winning Internet job board establishes new social and professional ... and health care community, LAKE WORTH, Fla., Oct. 9 ... care field, your job is extremely demanding, perhaps,even all-consuming. Finding ... tough, as is catching up on the latest industry news ...
Cached Medicine News:Health News:AWT, Inc. Continues Rapid Expansion in Middle East 2Health News:AWT, Inc. Continues Rapid Expansion in Middle East 3Health News:Many U.S. Hispanics Struggle With Health Care System 2Health News:2 UT Southwestern researchers elected to National Academy of Sciences' Institute of Medicine 2Health News:2 UT Southwestern researchers elected to National Academy of Sciences' Institute of Medicine 3Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 2Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 3Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 4Health News:Online Game from BrainGrade Can Raise Brain I.Q. 2Health News:Absolutely Health Care Launches MedicalMingle.com 2
... level. Incredibly quiet, yet very powerful. Attachment ... at one time eliminates the need to ... canister set-up is for Abbott 2000ml system ... and CE marks. Includes a wireless foot-switch. ...
Richardson Retractors...
Our most popular saline breast implant style for over 20 years. A full, rounded look that adds greater dimension to the breast....
Inquire...
Medicine Products: